Humanigen

Humanigen Equity Growth

Delisted

The Year-over-Year Equity Growth of Humanigen (HGENQ) as of Oct 30, 2026 is -97.43 %. In the previous year, Year-over-Year Equity Growth was -152.01 % — a change of -35.91% (higher).

Equity Growth

-97.43 %

YoY

-35.91%

Last updated:

Year-over-Year Equity Growth of Humanigen is 2022 -97.43 % . Year-over-Year Equity Growth of Humanigen was 2021 -152.01 % . It decreases by -35.91% higher compared to the previous year.

The Humanigen Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2015
-76.72 USD
Jan 1, 2016
-176.44 USD
Jan 1, 2017
-455.71 USD
Jan 1, 2018
66.68 USD
Jan 1, 2019
-76.57 USD
Jan 1, 2020
418.09 USD
Jan 1, 2021
-152.01 USD
Jan 1, 2022
-97.43 USD
The Humanigen Equity Growth history
YEAREquity GrowthYoY
-97.43 %-35.91%
-152.01 %-136.36%
418.09 %-646.00%
-76.57 %-214.83%
66.68 %-114.63%
-455.71 %+158.28%
-176.44 %+129.99%
-76.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

Year-over-Year Equity Growth of Humanigen is -97.43 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Humanigen since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Humanigen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humanigen

All Key Metrics — Humanigen